Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19

Rahul Kumar, Michael H. Lee, Claudia Mickael, Biruk Kassa, Qadar Pasha, Rubin Tuder, Brian Graham
ERJ Open Research 2020 6: 00405-2020; DOI: 10.1183/23120541.00405-2020
Rahul Kumar
1Dept of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rahul Kumar
  • For correspondence: rahul.kumar2@ucsf.edu
Michael H. Lee
1Dept of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Mickael
2Dept of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Biruk Kassa
1Dept of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qadar Pasha
3Functional Genomics Unit, CSIR-Institute of Genomics and Integrative Biology, Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rubin Tuder
2Dept of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Graham
1Dept of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian Graham
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Life cycle of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Based on the phylogenetic study, transmission of SARS-CoV-2 evolves from the natural reservoir of bats (non-human host) to the current pathogenic state of human outbreak through natural selection or another mammal, probably pangolin [15, 16] served as a host of a non-pathogenic version of the SARS-CoV-2 that later jumped into humans with the acquired capacity to current pandemic outbreak through human-to-human transmission [12, 19]. The viral ability to infect small and large animals under laboratory settings points to animals as an intermediate natural host [17, 18]. Based on a Centers for Disease Control and Prevention report, a very small number of pets, including dogs and cats, outside the USA were reported to be infected with the virus that causes coronavirus disease 2019 (COVID-19) after close contact with people with COVID-19. However, a tiger at a zoo and two pet cats in New York (NY, USA) have also tested positive for SARS-CoV-2 [18].

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Angiotensin-converting enzyme 2 (ACE2)-mediated counter regulation of the renin−angiotensin system (RAS). The ACE2-angiotensin (1–7) Mas axis (right side) counterbalances the harmful effects of the ACE1-angiotensin II type 1 receptors (AT1R) axis (left side). Angiotensinogen gets converted into angiotensin-I through enzymatic action of renin. ACE2 degrades angiotensin II and generates angiotensin (1–7) which antagonises the effects of angiotensin II. Moreover, clinical evidence suggests that RAS blockade by ACE inhibitors or AT1R blockers and mineralocorticoid antagonists enhance ACE2 level that is ultimately beneficial to the patients with cardiovascular diseases [23–26] but deleterious for coronavirus disease 2019 (COVID-19) patients [17, 22, 27]. The ACE inhibitor and angiotensin receptor blockers (as shown in red) antagonise the angiotensin II/AT1R axis.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    Biological mechanism of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Once the SARS-CoV-2 approaches the cell membrane, basal S1 subunit of viral spike glycoprotein binds to a membrane-bound molecule of angiotensin-converting enzyme 2 (ACE2). As more S1 subunits binds to membrane-bound molecules of ACE2, the membrane starts to form an envelope around the virus (an endosome). A cell membrane-bound serine protease, TMPRSS2, cleaves the S1 subunits of SARS-CoV-2 from its S2 subunits that mediated endosome entry into the cells (endocytosis). Inside the cell, viral genetic material is released by either acidification or by proteolysis (cathepsin). Viral replication and translation forms a new virion that cleaves out from cells by exocytosis. Of note, ACE2-mediated cardiovascular protection is lost following endocytosis of ACE2 with SARS-CoV-2 viral particles. The endocytosis triggers ADAM-17-mediated ectodomain shedding of tissue ACE2 [30, 31], which through the integrin pathway induces pathologic intracellular signalling [32]. Lack of ACE2 availability increases angiotensin II levels that result in detrimental effects due to increased activity of angiotensin-II type 1 receptor (AT1R) at the expense of ACE2/angiotensin (Ang) 1–7 driven protective pathways [34]. Viral infection also results in activation of circulatory inflammatory cytokines, antibody response and immune cells; these may damage airways epithelia. IL: interleukin; MCP: monocyte chemotactic protein 1.

  • FIGURE 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4

    Overall lung pathophysiology, immune cell activation and cytokine production. Severe acute respiratory syndrome-coronavirus-2 infects the upper respiratory tract. Most of the patients (∼80%) recover with mild-to-moderate upper respiratory symptoms. In the remaining patients, the virus reaches the lower respiratory track triggering pathologic immune response. Around 6% of the patients shows very severe symptoms of acute respiratory distress syndrome and require intensive care unit admission. Autopsies of patients with coronavirus disease 2019 (COVID-19) showed clusters of severe respiratory illness, including associated features of diffuse alveolar damage, such as diffuse type II pneumocyte hyperplasia, epithelial necrosis, fibrin deposition and hyaline membrane formation [80, 83, 96]. Most patients who died of severe acute respiratory syndrome-coronavirus developed acute respiratory distress syndrome with interstitial mononuclear inflammatory infiltrates [54, 75, 79, 80, 83, 97]. In addition, several nonspecific histological observations have also been observed that include oedema, fibrinous/proteinaceous exudates, hyperplastic pneumocytes, patchy interstitial chronic inflammation, and multinucleated giant cells with a dysregulated immune system that results in very high amounts of inflammatory cytokines [98]. PD1: programmed cell death protein-1; TIM3: T-cell immunoglobulin domain and mucin domain-3; NKG2A: killer cell lectin-like receptor subfamily C member 1; G-CSF: granulocyte-colony stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; IP10: interferon inducible protein-10; MCP1: monocyte chemotactic protein 1; TNF: tumour necrosis factor; IL: interleukin; Ig: immunoglobulin; IFN: interferon; IMs: interstitial macrophages.

  • FIGURE 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5

    Schematic summary of the potential therapeutic targets. Recapitulation of coronavirus disease 2019 (COVID-19) pathological conditions in global or cell-specific knockouts in the humanised angiotensin-converting enzyme (hACE2) mouse model will enable investigators to dissect the inflammatory immune cascades that are involved in disease pathology. As shown, the blockade of cell-specific receptors, T-helper (Th)1 and/or Th2 cytokines, complement activation, renin–angiotensin system pathway activity, administration of mesenchymal stem cells, and antithrombotic treatments could all be useful as therapeutic targets in COVID-19.

Tables

  • Figures
  • TABLE 1

    Key features of mouse models used in studies of coronavirus infections

    Mouse lineDisease modelKey findings[Ref.]
    WildtypeSARSSARS-CoV infections resulted into shedding of large amounts of infectious virus with the development of lung injury due to lowering of ACE2 expression[64]
    SARSSARS-CoV-infected C3−/− mice exhibited significantly less weight loss and less respiratory dysfunction with reduced lung pathology and lower cytokine and chemokine levels in both the lungs and the sera[65]
    Ace2−/−SARSSARS-CoV infections resulted in less shedding infectious virus with mild lung pathological changes due to reduced amount of spike RNA[64]
    ARDS/SARSACE2 blockade in mice resulted into enhanced vascular permeability, increased lung oedema, neutrophil accumulation, and worsened lung function[53, 64]
    Tmprss2−/−SARSSARS-CoV infection in Tmprss2−/− mice showed attenuated inflammatory chemokine and/or cytokine responses[33]
    COVID-19Transcriptional downregulation of Tmprss2 inhibits host SARS-CoV-2 entry.[63]
    Tmprss2−/− hDPP4-TgMERSTmprss2−/− murine models infected by MERS-CoV showed improved immunopathology[33]
    hACE2COVID-19Mouse model of COVID-19 showing similar pattern of human interstitial pneumonia with infiltration of significant macrophages and lymphocytes into the alveolar interstitium, and accumulation of macrophages in alveolar cavities following SARS-CoV-2 infection[6, 7, 66]
    hACE2COVID-19This model developed productive SARS-CoV-2 infection and inflammatory pulmonary infiltrates as seen in COVID-19 patients
    Evidence of inadequate antiviral activity and potential harms of endogenous type I IFN responses were observed
    [5]
    C3−/−SARSSARS-CoV-infected C3−/− mice exhibited significantly less weight loss and less respiratory dysfunction with reduced lung pathology and lower cytokine and chemokine levels in both the lungs and the sera[65]

    Ace2−/−: angiotensinogen converting enzyme 2 knockout; SARS: severe acute respiratory syndrome; CoV: coronavirus; C3−/−: complement 3 knockout; ARDS: acute respiratory distress syndrome; Tmprss2−/−: transmembrane protease, serine 2 knockout; COVID-19: coronavirus disease 2019; hDPP4-Tg: human dipeptidyl peptidase 4 transgene; MERS: Middle East Respiratory Syndrome; hACE-2: transgenic mice bearing human ACE2; IFN: interferon.

    PreviousNext
    Back to top
    Vol 6 Issue 4 Table of Contents
    ERJ Open Research: 6 (4)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
    Rahul Kumar, Michael H. Lee, Claudia Mickael, Biruk Kassa, Qadar Pasha, Rubin Tuder, Brian Graham
    ERJ Open Research Oct 2020, 6 (4) 00405-2020; DOI: 10.1183/23120541.00405-2020

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
    Rahul Kumar, Michael H. Lee, Claudia Mickael, Biruk Kassa, Qadar Pasha, Rubin Tuder, Brian Graham
    ERJ Open Research Oct 2020, 6 (4) 00405-2020; DOI: 10.1183/23120541.00405-2020
    Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • Abstract
      • Introduction
      • Origin of SARS-COV-2 and mode of transmission to humans
      • ACE2: a portal of entry for SARS-CoV-2
      • Role of animal models in elucidating the pathogenesis of COVID-19
      • The pulmonary pathophysiology of COVID-19
      • Potential molecular and biochemical therapeutic targets in the host
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF

    Subjects

    • Respiratory infections and tuberculosis
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Role of digital health in pulmonary rehabilitation
    • Healthcare experiences of adults with COPD in community care
    • Multimorbidity in bronchiectasis
    Show more Reviews

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About ERJ Open Research

    • Editorial board
    • Journal information
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Online ISSN: 2312-0541

    Copyright © 2023 by the European Respiratory Society